The Efficacy and Safety of Brolucizumab for the Treatment of nAMD: A Systematic Review and Meta-Analysis

Introduction: As demonstrated in pivotal clinical trials, brolucizumab can be used to treat neovascular age-related macular degeneration (nAMD) because it antagonizes vascular endothelial growth factor (VEGF) in the vitreous. However, brolucizumab may cause retinal vasculitis obliterans in the prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Chuan, Junlan, Liu, Lianqiao, Feng, Yumei, Wang, Mengdan, Li, Gang, Lv, Qin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136056/
https://www.ncbi.nlm.nih.gov/pubmed/35645802
http://dx.doi.org/10.3389/fphar.2022.890732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9136056/
https://www.ncbi.nlm.nih.gov/pubmed/35645802
http://dx.doi.org/10.3389/fphar.2022.890732

Ejemplares similares